Dr Sia Daneshmand speaks to ecancer about the results of the SEMS trial: a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.

He presented the results at the ASCO GU 2021 meeting.

Dr Daneshmand reports that out of a total of 55 patients, 82% patients were cured by the surgery and did not require additional therapy.

He adds that the remaining patients that recurred were either cured by subsequent therapy or chemotherapy.